Preeyaporn Klinjan

Preeyaporn Klinjan

Auto-generated profile, based on publicly available information

Preeyaporn Klinjan

Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Journal of Functional Foods
Verified
Journal Article
Open access
MTMingkwan Na Takuathung
Mingkwan Na Takuathung
STSupanimit Teekachunhatean
Supanimit Teekachunhatean
SCSunee Chansakaow
Sunee Chansakaow
PKPreeyaporn Klinjan
Preeyaporn Klinjan
RIRatchanon Inpan
Ratchanon Inpan
NKNut Koonrungsesomboon
Nut Koonrungsesomboon

1 June 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
TKTattiya Kantasa
Tattiya Kantasa
KYKankanit Yeerong
Kankanit Yeerong
PKPreeyaporn Klinjan
Preeyaporn Klinjan
MTMingkwan Na Takuathung
Mingkwan Na Takuathung
KSKornvipa Settakorn
Kornvipa Settakorn
NKNut Koonrungsesomboon
Nut Koonrungsesomboon
Psoriasis is a chronic inflammatory skin disease characterized by thickened, erythematous, and scaly plaques that significantly impact patients’ quality of life. Although various treatments are available, they often cause adverse effects, prompting the exploration of alternative therapies. Curcumin, a bioactive compound in Curcuma longa Linn. (turmeric), has demonstrated potential benefits in managing psoriasis. This article aims to comprehensively evaluate the anti-psoriatic activity, efficacy, and safety profiles of curcumin and its novel formulations, as well as to discuss future directions for enhancing their use as an alternative treatment for psoriasis. Curcumin exerts its anti-psoriatic effects through multi-targeted actions, including inhibiting cell proliferation, inducing apoptosis, suppressing pro-inflammatory cytokines, and enhancing skin barrier proteins, thereby alleviating psoriasis lesions. However, both oral and topical curcumin formulations face challenges, such as low bioavailability and limited skin penetration, underscoring the need for novel formulations to improve therapeutic outcomes. Clinical findings suggest that oral curcumin may provide greater efficacy and better tolerance as an adjunctive therapy for moderate to severe psoriasis, while topical formulations may help reduce severity and improve well-being in mild to moderate cases. Overall, curcumin and its novel formulations show promise as therapeutic agents for psoriasis treatment. However, further research, particularly large-scale clinical trials, is essential to evaluate long-term efficacy and safety comprehensively.